2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

AnnJi Pharmaceutical Co. Ltd.(安基)

Company Presentations

Wednesday, July 22 Company Company Presentations 2–Biotech

AnnJi Pharmaceutical Co. Ltd.(安基)

Company Info

Name /AnnJi Pharmaceutical Co. Ltd.(安基)

Address /B405, No. 18, Siyuan St., Zhongzhgng District, Taipei, Taiwan

Website /www.ajpharm.com/wp/

Presenter

Name /Karen Lin

Title /Senior Manager

Email /karen.lin@ajpharm.com

Telephone /(Work) (886)223655677 ext 300

Fax /

Mobile /0972700609

Company Type

Biotechnology,Pharmaceutical

About the Company

AnnJi Pharmaceutical Co. Ltd. (AnnJi) is specialized in target-based discovery, translation and early development of novel, druggable small-molecules. We focus on first-in-class and/or best-in-class drug candidates for diseases and conditions of high unmet-needs; such as, selective histone deacetylase (HDAC) inhibitors for neuropathic pain and fibrosis, and phosphodiesterase (PDE) inhibitors for the treatment of inflammatory diseases. AnnJi aims to develop innovative therapies for the global market, and aspires to be Taiwan’s leading drug developer in dermatology and neurology.

Brief Description of main products or services

AnnJi has expertise spanning from lead generation to early clinical development. Novel compound leads are rationally designed through structural insight of selected protein targets and their key role(s) in disease pathophysiology; followed by lead optimization for drug likeness (structure activity relationship), the selection of preclinical drug candidates via rigorous in vitro, in vivo proof-of-concept investigations, and taken into first-in-human trial. The team at AnnJi has produced a pipeline of highly differentiated lead molecules that have superior safety profile, pharmacological activities, and therapeutic window compared to the current treatment regimen or investigational candidates in clinic. Our leading HDAC6 selective inhibitor for chemotherapy-induced peripheral neuropathy and difficult-to-treat fibrotic conditions such as idiopathic pulmonary fibrosis and cystic kidney disease will enter clinical phase in 2021, followed by the PDE4 specific inhibitor for psoriasis.  In addition to compounds discovered organically, AnnJi is actively seeking opportunities to in-license and/or codevelop new drug in our focused therapeutic areas.  The combination of our talented and specialized staffs, R&D pipeline, state-of-art research infrastructure, and a culture of integrity, compassion, teamwork that drives for excellence makes AnnJi a strong and unique team of choice to venture capitalists, biotech partners, and collaborators from academia and pharmaceutical companies.

Contact Person

Name /Karen Lin

Email /karen.lin@ajpharm.com

Phone /(Work) (886)223655677 ext 300